Hans Moebius has joined Athira Pharma as chief medical officer. Moebius’s experience includes positions at Ciba-Geigy, Novartis (NYSE: [[ticker:NVS]]), Merz Pharma, TauRx, and Allergan (NYSE: [[ticker:AGN]]). Seattle-based Athira, which recently changed its name from M3 Biotechnology, is currently testing lead drug candidate NDX-1017 in a Phase 1 study in patients with Alzheimer’s disease, dementia, or mild cognitive impairment.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
